The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    GSK has signed its fifth licensing deal with a China-based drugmaker since the start of 2025, agreeing to pay Chimagen Biosciences up to $750 million for a three-pronged T-cell engager for multiple myeloma.

    Updated 21 hours ago
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA clears first generic radioligand drug; Sionna turns to layoffs

    A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

  • A photo of the packaging for the spinal muscular atrophy drug Isemblyd.
    Image attribution tooltip
    Courtesy of Scholar Rock
    Image attribution tooltip

    Scholar Rock SMA drug approved by FDA

    Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies. 

    FDA
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

    RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

  • Gloved workers supervise rows of glass bottles on a pharmaceutical production line.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    mRNA cancer vaccines’ biggest barriers to market

    Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca’s newly approved pill fails frontline breast cancer study

    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.

    Updated Sept. 11, 2026
  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Electra Therapeutics set terms for an offering that could net the company more than $300 million, according to a Monday filing.

    Updated Sept. 14, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

    Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

  • A photo of Takeda president of R&D Andy Plump.
    Image attribution tooltip
    Permission granted by Takeda
    Image attribution tooltip

    Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

    Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA places partial hold on Biohaven’s epilepsy drug

    Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

    FDA
  • An illustration of pain in the colon.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    A new immuno-oncology play raises $225M for a next-generation drug

    Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Trump administration

    FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders

    After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said. 

    FDA
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis RNA drug falls short in rare muscle disease study

    The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tyra disappoints investors with bladder cancer data

    Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

  • A person in a white sweater holds a drug injection pen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Kura spins diabetes work into a Lilly-backed biotech startup

    Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

  • A stethoscope rests on top of an EKG printout. A cool blue cast dominates the scene.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

    Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

    Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

    One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

  • A photo of Moonwalk Biosciences' executive team.
    Image attribution tooltip
    Permission granted by Erin Beach
    Image attribution tooltip
    Obesity drugs

    Moonwalk reloads with $70M and new RNAi prospects for obesity

    The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: China deals, stock flatlines and Lilly’s M&A spree

    Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

  • An exterior photo of Seattle Children's Hospital.
    Image attribution tooltip
    Courtesy of Seattle Children's Hospital
    Image attribution tooltip

    BrainChild hauls in $116M to make cell therapies for childhood brain cancers

    Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

    Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Trailing rivals, AbbVie scores win with dual-acting myeloma drug

    The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

  • A technician in protective clothing stands beside manufacturing equipment in a pharmaceutical laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The hidden scale-out problem behind CAR-T’s growth

    CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.